Archibald Lord, MD
Internal Medicine · Charlottesville, VANPI 1427048446
Payments from drug & device makers
Across 561 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$949
- AstraZeneca$876
- Johnson & Johnson$716
- Lilly USA, LLC$566
- Pfizer$464
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,90597%
- Education$2823%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 173 | $1,792 |
| AbbVie(2 entities) | 85 | $949 |
| AstraZeneca | 13 | $876 |
| Johnson & Johnson | 49 | $716 |
| Lilly USA, LLC | 68 | $566 |
| Pfizer | 22 | $464 |
| Abbott | 33 | $428 |
| Esperion Therapeutics, Inc. | 23 | $368 |
| Astellas Pharma US Inc | 20 | $349 |
| GSK | 5 | $159 |
| Bayer | 5 | $147 |
| Boehringer Ingelheim | 3 | $143 |
| Biohaven Pharmaceuticals, Inc. | 5 | $142 |
| Insightec,inc | 1 | $111 |
| Exact Sciences | 6 | $103 |
| Merck | 5 | $103 |
| Amgen(2 entities) | 6 | $102 |
| Amarin Pharma, Inc. | 5 | $95 |
| Dexcom, Inc. | 4 | $75 |
| Lundbeck LLC | 4 | $68 |
| Neurocrine Biosciences, Inc. | 4 | $59 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 4 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Novartis | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Biogen | 1 | $22 |
| Insulet Corporation | 1 | $21 |
| SK Life Science, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,187 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 638 | $290,512 |
| OzempicSemaglutide | 60 | $71,469 |
| MounjaroTirzepatide | 49 | $57,023 |
| XareltoRivaroxaban | 79 | $56,858 |
| MyrbetriqMirabegron | 133 | $50,779 |
| FarxigaDapagliflozin Propanediol | 48 | $44,311 |
| RybelsusSemaglutide | 16 | $36,186 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $32,419 |
| Repatha SureclickEvolocumab | 39 | $31,507 |
| KerendiaFinerenone | 30 | $30,495 |
| CreonLipase/Protease/Amylase | 19 | $28,209 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $28,059 |
| JardianceEmpagliflozin | 32 | $21,643 |
| JanuviaSitagliptin Phosphate | 17 | $18,529 |
| RestasisCyclosporine | 32 | $18,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $464 | $290,512638 claims |
| Novo NordiskOzempic, Rybelsus | $1,792 | $107,65576 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $876 | $76,73075 claims |
| Lilly USA, LLCMounjaro | $566 | $57,02349 claims |
| Johnson & JohnsonXarelto | $716 | $56,85879 claims |
| Astellas Pharma US IncMyrbetriq | $349 | $50,779133 claims |
| AbbVieCreon, Restasis | $949 | $46,35751 claims |
| BayerKerendia | $147 | $30,49530 claims |
| Boehringer IngelheimJardiance | $143 | $21,64332 claims |
| MerckJanuvia | $103 | $18,52917 claims |
| NovartisEntresto | $38 | $4,80511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Charlottesville
- James ClarkCharlottesville$16.2M
- Michael DevittCharlottesville$3.5M
- Sue BrownCharlottesville$2.4M
- Jeffrey SturekCharlottesville$156K
- Leroy VaughanRichmond$20.8M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.